|May 29, 2003
|HEMISPHERX PARTICIPATES IN ANTI-SARS FORUM
|Hemispherx Gives Keynote Speech at “Anti-SARS Forum”
Organized by Sino-American Pharmaceutical Association
Philadelphia, PA, Thursday, May 29, 2003: Hemispherx Biopharma, Inc. (AMEX: HEB) announced today that it has accepted an invitation to deliver a Keynote speech at the coming Sino-American Pharmaceutical Professionals Association (SAPA) Anti-SARS Forum, to be held at the Houston Hall, University of Pennsylvania, from 1:30 to 5:30 pm on Sunday June 1, 2003. The speech, titled “Natural Immunological and Antiviral Approach to SARS” will be given by Dr. William A. Carter, CEO of Hemispherx, who is the author on two textbooks on Antiviral Research and of more then 200 scientific articles in peer reviewed journals during his tenure at various academic institutions including Johns Hopkins University.
About the SAPA Conference
“The purpose of this forum is to educate publics about SARS, discuss opportunities and strategies of drug and vaccine R&D for SARS and to bridge the US pharma/biotech with Chinese government/pharma/biotech to fight SARS together. Officers from the Chinese Consulate will attend the forum and may explain the China policies about special green channel for fast approval for foreign company’s anti-SARS agents. After the presentation there will be a panel or round table discussion joined by managers and scientists from local pharmaceutical companies such as Merck, Wyeth, Glaxo Smith Kline (GSK), Johnson & Johnson, Bristol Meyers Squibb, AstraZenica, etc. The conference is sponsored by major pharmaceuticals such as Merck, GSK, and Wyeth, as well as several biotechnology companies. The Greater Philadelphia area is one of the major homes for the world pharmaceutical industry. It hosts six of the world’s top-ten largest pharmaceutical companies, as well as many mid/small pharma/biopharma companies and academic institutions.”
About the Sino-American Pharmaceutical Professionals Association (SAPA)
“SAPA was founded in 1993 as a non-profit organization with its headquarters in the greater New York area (NJ/NY/CT). SAPA has grown rapidly and has become one of the most active and well-recognized professional organizations in the United States. SAPA’s mission is to foster personal and professional career development of its members, promote scientific exchange, education and networking opportunities between the pharmaceutical industry and health care sectors.”
About the Company’s SARS programs
Hemispherx has in development several programs to potentially combat SARS with the use of its lead compounds Alferon N Injection®, a natural source, multispecies alpha interferon product, and Ampligen®, a double stranded RNA experimental product acting potentially as an immunomodulator and antiviral. The programs cover procedures for combating the effects of coronavirus-induced conditions by the administration of Alferon N Injection® or the experimental compound Ampligen® or in combination therapy. The Company will release updates on these programs in due time.
Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Its flagship products include Alferon and the experimental immunotherapeutics/antivirals Ampligen and Oragens. These novel proteins, approved for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has approximately 400 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net.
Hemispherx Biopharma, Inc.,
Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6223
HEB's Web Site: www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including AmpligenÒ and Oragensä) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic AlferonÒ do not imply that the product will ever be specifically approved commercially for these other treatment indications. The Alferon® asset for overseas sales for a category of STD is currently being acquired by the Company as part of a multi-step purchase contract of inventory, intellectual property, commercial licenses and GMP approved facilities, which house the biological operations.